Table 1– First- and second-line drugs available to treat susceptible and multidrug-resistant tuberculosis in five European Union Countries
DrugCountries where utilised n/5 totalCountries where not registeredAvailability
RarelyGenerallyAlways
First-line oral agents
 Isoniazid5AA–E
 Rifampicin5AA–E
 Ethambutol5AA–E
 Pyrazinamide5AA–E
Injectables
 Streptomycin5EA–D
 Amikacin5B, EA, C, D
 Kanamycin3AEA–C
 Capreomycin5AB, EA, C, D
Fluoroquinolones
 Ciprofloxacin#4B–E
 Ofloxacin#5A–E
 Levofloxacin2BEC, D
 Moxifloxacin5A, EB, C, D
 Gatifloxacin1BC
Oral bacteriostatic
 Etionamide3ECBD
 Protionamide4ACA, B, E
 Para-aminosalicylic acid5ACB, EA, D
 Cycloserine5ACEA, B, D
 Terizidone2ECB
 Thiacetazone1B, EC
 Rifabutin4EB, C, D
 Amoxicillin/Clavulanic acid4BEAC, D
 Clarithromycin5AB–E
 Clofazimine3ECB, D
 Linezolid4AB, C, D
 Inmipenem/Cilastatin1BC
  • A: former Soviet Union, intermediate tuberculosis (TB) incidence, high multidrug-resistant (MDR)-TB prevalence; B: northern Europe, low TB incidence, low MDR-TB prevalence; C: southern Europe, low TB incidence, low MDR-TB prevalence; D: southern Europe, intermediate TB incidence, low MDR-TB prevalence; E: central Europe, intermediate TB incidence, low MDR-TB prevalence. #: not recommended if later-generation fluoroquinolones are available [10].